期刊文献+

两种胰岛素强化治疗方案对血糖控制不佳2型糖尿病的临床疗效和安全性比较 被引量:3

The clinical efficacy and safety of two kinds of insulin intensive treatment program for bad-controlled type 2 diabetes patient
下载PDF
导出
摘要 目的探讨两种胰岛素强化治疗方案治疗血糖控制不佳2型糖尿病的临床效果及用药安全性。方法选取2010年3月~2011年2月本院门诊和住院部收治的2型糖尿病患者84例,随机分为对照组与观察组,分别采取诺和灵R+N和诺和锐30治疗。结果观察组治疗后空腹血糖(FPG)、餐后2h血糖(2hPG)和糖化血红蛋白(HbA1c)均明显降低(P<0.05),但组间比较差异无统计学意义(P>0.05);两组达标时间比较差异无统计学意义(P>0.05);观察组胰岛素用量明显少于对照组,差异有统计学意义(P<0.05);观察组低血糖发生率为4.76%,明显低于对照组(P<0.05)。结论诺和锐30治疗血糖控制不佳2型糖尿病疗效显著,可有效控制患者血糖水平,降低低血糖发生率,安全性高。 Objective To investigate the clinical effect and safety of two kinds of insulin intensive therapy regimens in the treatment of bad-controlled type 2 diabetes patients. Methods Eighty four cases of type 2 diabetes patients treated from March 2010 to February 2011 in our hospital outpatient and inpatient department, were randomly divided into control group and observation group, respectively took Novolin R+N and insulin aspart 30 treatment. Results The FPG, 2hPG and HbAlc of observation group were decreased (P 〈 0.05), but two groups were not significantly different (P 〉 0.05); standard time comparison between two groups showed no significant difference (P 〉 0.05); insulin dosage of ob- servation group were less than those of control group, the difference had statistics significance (P 〈 0.05); hypoglycemia incidence rate of the observation group was 4.76%, which was significantly lower than that of the control group (P 〈 0.05). Conclusion The clinical efficacy of insulin aspart 30 in treatment of bad-controlled type 2 diabetes patient were curative, it can effectively control the blood glucose level, and reduce the incidence of hypoglycemia, high security.
作者 郭美桃
出处 《中国当代医药》 2013年第8期82-83,共2页 China Modern Medicine
关键词 胰岛素强化治疗 2型糖尿病 临床疗效 安全性 Intensive insulin therapy Type 2 diabetes Clinical efficacy Safety
  • 相关文献

参考文献8

二级参考文献34

  • 1许樟荣.护士在糖尿病教育和管理中承担着重大责任[J].中华护理杂志,2004,39(10):727-729. 被引量:323
  • 2陈萍.诺和锐治疗糖尿病的临床观察[J].实用糖尿病杂志,2006,2(4):36-37. 被引量:8
  • 3蔡迎九.短期胰岛素泵强化治疗对初发2型糖尿病病人胰岛β细胞功能的影响[J].临床医学,2007,27(3):34-35. 被引量:4
  • 4[1]D.M.Nathan&J.B.Buse&M.B.Davidson& E.Ferrannini&R.R.Holman&R.Sherwin&B.Zinman.Management of hyperglycaemia in type 2 diabetes mellitus:a consensus algorithm for the initiation and adjustment of therapy.Diabetologia.2008,51:8-11.
  • 5[2]Matthew C.Riddle,Julio Roaenstock,and John Gerich,Randomized addition of glargine or human NPH insulin to oral therapy of type2 diabetic patients,Diabetes Care.2003,26:3080-3086.
  • 6[3]Julio Rosenstock,Sherwyn L Schwartz,Charles M.Clark,et al.Basal Insulin Therapy in Type 2 Diabetes.Diabetes Care.2001,24:631-636.
  • 7[4]Michael F.Bullano,Maxine D.Fisher,W.Daniel Grochulski,Laura Menditto and Vincent J.Willey,Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products,American Journal of Health-System Pharmacy.2006,63(24):2473-2482
  • 8陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2010:282.
  • 9潘长玉.关注糖尿病血糖治疗达标的安全性隐患[J].中华内分泌代谢杂志,2007,23(4):289-290. 被引量:47
  • 10陈灏珠.实用内科学[M].北京:人民卫生出版社,2005.1850.

共引文献58

同被引文献15

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部